Results 141 to 150 of about 4,524 (166)

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Induction and Enhancement of Bacteriocin Production (Review)

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Conventionally, bacteriocins are produced by microorganisms on complex substrates, released as semi‐purified preparations or crude fermentates. These bacteriocin‐containing products often exhibit unsatisfactory purity, low active‐substance content, and high production costs, limiting their commercialization and use. This review aims to analyze
Oksana Knysh, Artur Martynov
wiley   +1 more source

Beyond wound sealing: A dual‐functional adhesive nanofiber membrane promoting coagulation and osteogenesis in extraction sites

BMEMat, EarlyView.
Inspired by the suction mechanics of octopus suckers, a dual‐layer nanofiber membrane integrates antibacterial protection, strong wet adhesion, and osteogenic support, offering a bioinspired strategy for effective hemostasis and alveolar bone preservation.
Huijing Ma, Liheng Gao, Hao Liang, Wentao Jiang, Junyi Wang, Jiajia Wang, Shuhan Duan, Lingxi Meng, Adilijiang Yimiti, Wenjie Zhang   +9 more
wiley   +1 more source

Consistency of fasting blood glucose & oral glucose tolerance test: a hospital based study in Bangladesh

Journal of Diabetology, 2015
M.S.H Talukder, A.K.A Khan, S.M.K Ali, S Vaaler, A Hussain   +4 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Stephen Sonis, Noam Yarom, Michal Kuten-Shorrer   +2 more
exaly  

Evidence that human oral glucose detection involves a sweet taste pathway and a glucose transporter pathway

PLoS ONE, 2021
Paul Breslin, Linda Flammer, Nancy Rawson   +2 more
exaly  

Oral complications of cancer and cancer therapy

Ca-A Cancer Journal for Clinicians, 2012
Juliette Thariat, Andrei Barasch, Joel Epstein   +2 more
exaly  

Oral cavity and oropharyngeal squamous cell carcinoma—an update

Ca-A Cancer Journal for Clinicians, 2015
Angela Chi
exaly